An Open-Label, Non-Randomized, Pharmacokinetic and Safety Study of Multiple Oral Doses of SB-480848 in Healthy Subjects and Subjects With Moderate Hepatic Impairment
Phase of Trial: Phase I
Latest Information Update: 29 Jul 2017
At a glance
- Drugs Darapladib (Primary)
- Indications Asthma; Atherosclerosis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors GlaxoSmithKline
- 29 Jul 2017 Last checked against ClinicalTrials.gov record.
- 11 Aug 2011 Actual end date (Oct 2010) added as reported by ClinicalTrials.gov.
- 11 Aug 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.